Canary RX Receives its Health Canada Sales License

2.3 min readPublished On: September 16th, 2021By

NORFOLK COUNTY, ON — Target Group Inc. (OTCQB: CBDY) reported that its wholly owned subsidiary, Canary Rx Inc.  has received its Health Canada sales license.

Under its Sales License, Canary RX announced that is now authorized to manufacture and sell Cannabis product’s directly to provincial distributors and other authorized Canadian retail supply channels, permitting the organization to execute on its future CPG strategy of bringing high-quality, strategically segmented consumer brands to market as well as providing third-party processing and co-packing services on behalf of other licensed white-label partners.

Canary RX, through its joint venture partnership, Venn Cannabis, has been working meticulously to ensure production of ultra-premium, craft cannabis in its Simcoe, Ontario production facility. This will ultimately enable delivery of its unique genetic offerings and provide a strong platform for other retail brands in the market to build a portfolio of whole flower consumer products. The company has already successfully transacted with several additional licenced producers and is very optimistic that over the next 12-18 months, can establish itself as a leader in contract-based craft cultivation at scale within the Canadian cannabis landscape.

“This is an important and significant milestone for us completing another licensing certification required to execute on our commercial strategy. Receiving the sales license at our Simcoe, Ontario facility is tremendously positive news for Canary RX and VENN, our joint-venture with Thrive Cannabis,” said Tony Zarcone, CEO of Target Group & Canary RX Inc.

Forward-Looking Statements Disclaimer: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainties and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov.

(This information is primarily sourced from Target Group Inc.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

 

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

  • Industrial Hemp Market

Global Industrial Hemp Market Report 2022

December 6th, 2022|

Dublin - According to the publisher, the global industrial hemp market size is estimated to be valued at USD 6.8 billion in 2022 and is projected to reach USD 18.1 billion by 2027, recording a ...